# Indian Pharma Risk Aversion

> Indian pharma leaders say risk aversion blocks innovation, urging tech adoption for faster drug development.
- Title: Indian Pharma Risk Aversion · The Economic Times | Shortify
- Summary: Indian pharma leaders say risk aversion blocks innovation, urging tech adoption for faster drug development. Indian pharma companies face innovation delays…
- Keywords: indian pharma, risk aversion, innovation, tech adoption, drug development, biocon, sun pharma, glenmark pharma, vikkshit bharat, Indian, Pharma, Risk
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharmas-risk-aversion-holding-back-innovation-kiran-mazumdar-shaw/articleshow/134860200.cms
- Author: Vikas Dandekar
- Published: 2026-10-10T18:43:00+00:00
- Read time: 1 min
- Topics: indian pharma, risk aversion, innovation, tech adoption, drug development, biocon, sun pharma, glenmark pharma, vikkshit bharat
## Pharma Risk Aversion
Indian pharmaceutical industry's risk aversion hinders innovation, requiring tech adoption for faster drug development.

> In pharma and biopharma, the pipeline is the lifeline
## Drug Pipeline Challenges
Only one or two out of 10 drug candidates reach final stages and commercial milestones.
## Biocon's Progress
Biocon advanced an anti-cancer drug to Phase III clinical trials.
## Regulatory Momentum
India's regulatory process is gaining momentum for faster drug approvals.
## Sun Pharma Acquisition
Sun Pharma acquired US-based Organon for $11.75 billion to boost global innovative drug launches.
## Future Innovation Strategy
Indian pharma companies need tech adoption to leapfrog global competitors and accelerate drug development.
## Key takeaway

Indian pharma companies face innovation delays due to risk aversion, with leaders calling for tech adoption to accelerate drug development.